Lineage Cell Therapeutics Inc. Common Stock (LCTX)

FairStock Score: 45/100 — MIXED

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.05, providing financial flexibility
• Revenue growth of 130.4% demonstrates strong top-line momentum

Concerns

• Altman Z-Score of -2.0 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Lineage Cell Therapeutics Inc. Common Stock is a micro-cap healthcare company valued at $397 million. The business generates $15 million in annual revenue with a 5.8% net margin. From a quality standpoint, Lineage shows distressed Altman Z-Score of -2.0 warrants caution and negative ROE indicating losses. Growth dynamics show revenue growing at 130.4% and profit growth of 126.0%. Our composite FairStock Score of 45/100 reflects mixed fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Lineage's 130% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer